ட ஸ்ரீநிவாஸ் சிவப்பு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ட ஸ்ரீநிவாஸ் சிவப்பு. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ட ஸ்ரீநிவாஸ் சிவப்பு Today - Breaking & Trending Today

Optimus Pharma gets DCGI nod for conducting Phase III Clinical Trials for Molnupiravir on patients with mild to moderate COVID-19

Hyderabad (Telangana) [India], May 25 (ANI/PRNewswire): Optimus Pharma on the 19th of May 2021 received DCGI nod for conducting Phase III Clinical Trials for orally administered Molnupiravir capsules on patients with Mild to Moderate Covid-19 patients.
With severe shortage of antiviral drugs in the market against the SARS-CoV-2 infection, it is imperative that more drugs with potent antiviral activity against SARS-CoV-2 be introduced.
Optimus Pharma said having internally developed the active pharmaceutical ingredient (API) and the formulations for the product, it had filed for clinical trials with the DCGI. The regulator gave nod for conducting the trial on mild to moderate patients. ....

Drd Srinivas Reddy , Optimus Pharma , Expert Committee , Managing Director , Subject Expert Committee , Drd Srinivas Reddy , Optimus Pharma , Clinical Trials , ட ஸ்ரீநிவாஸ் சிவப்பு , உகந்த பார்மா , நிபுணர் குழு , நிர்வகித்தல் இயக்குனர் , பொருள் நிபுணர் குழு ,

Drugs manufacturer from Hyderabad on overdrive

Drugs manufacturer from Hyderabad on overdrive
ANI |
Updated: May 19, 2021 13:15 IST
Hyderabad (Telangana) [India], May 19 (ANI/PNN): Optimus Pharma on Tuesday received DCGI nod for conducting Phase III Clinical Trials for orally administered Molnupiravir capsules on patients with Mild and Moderate Covid-19 symptoms.
With a severe shortage of antiviral drugs in the market against the SARS-CoV-2 infection, it is imperative that more drugs with potent antiviral activity against SARS-CoV-2 be introduced.
Optimus pharma said having internally developed the active pharmaceutical ingredient (API) and the formulations for the product, it had filed for clinical trials with the DCGI. The regulator gave a nod for conducting the trial on mild and moderate patients on May 18 2021. ....

Drd Srinivas Reddy , Optimus Pharma , Expert Committee , Managing Director , Subject Expert Committee , Drd Srinivas Reddy , Optimus Pharma , ட ஸ்ரீநிவாஸ் சிவப்பு , உகந்த பார்மா , நிபுணர் குழு , நிர்வகித்தல் இயக்குனர் , பொருள் நிபுணர் குழு ,

Covid treatment: Optimus Pharma gets DCGI nod for phase 3 trials of Molnupiravir

May 19, 2021
The orally administered drug is being tested for treating mild and moderate infection
Optimus Pharma has received the approval of the Drug Controller General of India (DCGI) to conduct Phase III clinical trials of orally administered Molnupiravir capsules on patients with mild and moderate Covid-19 infection.
As per the clinical trial protocols approved, a total of 2,500 subjects in both mild and moderate Covid-19 will be randomised in the study in a 1:1 ratio to Molnupiravir with standard supportive care or standalone standard supportive care.
Treatment modes
The treatment duration is a maximum of five days and the total study duration will be maximum for 29 days from randomisation, the Hyderabad-based company said in a release on Wednesday. ....

Andhra Pradesh , Drd Srinivas Reddy , Optimus Pharma , Drug Controller General , Srinivas Reddy , Managing Director , Covid 19 , Dcgi Nod , Phase 3 Trials , ஆந்திரா பிரதேஷ் , ட ஸ்ரீநிவாஸ் சிவப்பு , உகந்த பார்மா , மருந்து கட்டுப்படுத்தி ஜநரல் , ஸ்ரீநிவாஸ் சிவப்பு , நிர்வகித்தல் இயக்குனர் , சர்வதேச பரவல் , கட்டம் சோதனைகள் ,

Optimus Pharma to conduct Ph III trials for Molnupiravir capsules on COVID-19 patients

2500 subjects with mild to moderate COVID-19 will be randomised in the study in a 1:1 ratio to Molnupiravir ....

Andhra Pradesh , Drd Srinivas Reddy , Optimus Pharma , Managing Director , ஆந்திரா பிரதேஷ் , ட ஸ்ரீநிவாஸ் சிவப்பு , உகந்த பார்மா , நிர்வகித்தல் இயக்குனர் ,

Optimus Pharma gets nod for phase 3 trials of Molnupiravir capsule

Optimus Pharma gets nod for phase 3 trials of Molnupiravir capsule
Updated:
Updated:
Share Article
AAA
Drug-maker Optimus Pharma on Wednesday said it received approval of the Drugs Controller General of India (DCGI) to conduct Phase III clinical trials for Molnupiravir capsule on mild and moderate COVID-19 patients.
As per the clinical trial protocols approved, a total of 2,500 subjects in both mild and moderate COVID-19 will be randomised in the study in a 1:1 ratio to Molnupiravir with standard supportive care or standalone standard supportive care. The treatment duration is a maximum of five days and the total study duration will be a maximum of 29 days from randomisation, the release said. ....

Drd Srinivas Reddy , Optimus Pharma , Drug Maker Optimus Pharma , Drugs Controller General , Phase 3 , ட ஸ்ரீநிவாஸ் சிவப்பு , உகந்த பார்மா , மருந்துகள் கட்டுப்படுத்தி ஜநரல் ,